Journal articleNature2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
- Journal
- Nature
- Published
- 8 April 2024
- Citations
- 387
- License
- cc by
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
Grants 7
- Defining the roles of ERK MAPK in driving KRAS-mutant pancreatic cancer growth. F32CA239328↗
- Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer K22CA276632↗
- Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer K99CA276700↗
- SToP Cancer SPORE: Administrative Core A P50CA257911↗
- Mechanistic Basis for ERK in driving KRAS-dependent pancreatic cancer R00CA276700↗
- Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer R01CA276268↗
- Targeting undruggable RAS for cancer treatment R35CA232113↗